Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
09/2000
09/05/2000US6114520 5'-deoxy-cytidine derivatives
09/05/2000US6114517 Methods of modulating tumor necrosis factor α-induced expression of cell adhesion molecules
09/05/2000US6114388 Monofunctional and/or polyfunctional polylysine conjuages
09/05/2000US6114372 Matrix metalloproteinase (mmp); tumor necrosis factor(tnf); compounds such as n2-((2s)-acetylmercapto)acetyl-5-phthalimidopentanoyl)-n1-((4 -methoxybenzene)sulphonyl)-n1-(phenylmethyl)hydrazine
09/05/2000US6114367 Such as 3-(3-cyclopentyloxy-4-methoxy)phenyl-2-isoxazoline-5-hydroxamic acid; treating sepsis, septic shock, inflammatory bowel disease, tuberculosis, graft versus host disease or cachexia associated with aids or cancer in a mammal
09/05/2000US6114365 Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
09/05/2000US6114361 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
09/05/2000US6114358 Thrombin inhibitors
09/05/2000US6114335 Benzoylguanidine derivatives, process for their preparation their use in the preparation of medicines
09/05/2000US6114332 Bis(acridinecarboxamide) and bis(phenazinecarboxamide) as antitumor agents
09/05/2000US6114328 Isoxazoline and isoxazole fibrogen receptor antagonists
09/05/2000US6114317 Method of locking 1α-OH of vitamin D compounds in axial orientation
09/05/2000US6114316 Combination of bisphosphonate and tetracycline
09/05/2000US6114161 Isolated streptococcus sp pt strain dsm 8747 which produces a lipoteichoic acid used as an anticarcinogenic agent
09/05/2000US6113906 Water-soluble non-antigenic polymer linkable to biologically active material
09/05/2000US6113900 Use of IL-2 receptor-targeted therapeutics to inhibit allograft rejection and treat autoimmune disorders
09/05/2000US6113899 Antagonists of chaperonin 10
09/05/2000US6113898 Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
09/05/2000CA2116442C Novel glycosphingolipids and the use thereof
09/05/2000CA2045593C Use of 1,2-benzopyrone derivatives for the treatment of malignant tumours in humans
08/2000
08/31/2000WO2000050639A2 Gene sequence variations with utility in determining the treatment of disease
08/31/2000WO2000050633A1 Method for cloning signal transduction intermediates
08/31/2000WO2000050618A1 Virus vector
08/31/2000WO2000050607A2 Goodpasture antigen binding protein
08/31/2000WO2000050597A2 Neutrokine-alpha and neutrokine-alpha splice variant
08/31/2000WO2000050595A2 Nucleic acid molecules associated with melanoma and thyroid tumors
08/31/2000WO2000050590A1 Mdm interacting protein and methods of use thereof
08/31/2000WO2000050565A2 Compositions, kits, and methods relating to the human fez1 gene, a novel tumor suppressor gene
08/31/2000WO2000050562A2 Dna encoding snorf25 receptor
08/31/2000WO2000050454A1 Androgen-induced suppressor of cell proliferation and uses thereof
08/31/2000WO2000050453A1 A novel inhibitor of programmed cell death
08/31/2000WO2000050449A1 Process for production diphtheria toxin
08/31/2000WO2000050445A1 Novel component of von hippel-lindau tumor suppressor complex and scf ubiquitin ligase
08/31/2000WO2000050441A1 Novel substituted 11.beta steroid derivatives, method for preparing same and intermediates of said method, use as medicine and compositions containing them
08/31/2000WO2000050431A1 Platinum (ii) compounds
08/31/2000WO2000050427A1 Optically pure camptothecin analogues
08/31/2000WO2000050423A1 C-21 modified epothilones
08/31/2000WO2000050417A1 Anti-cancer dihydroquinazoline derivatives
08/31/2000WO2000050400A1 2-aminopyridines containing fused ring substituents
08/31/2000WO2000050395A1 Sulfonamide-containing indole compounds
08/31/2000WO2000050086A1 Molecules for the treatment and diagnosis of tumors
08/31/2000WO2000050082A1 Combination therapy for lymphoproliferative diseases
08/31/2000WO2000050071A1 PROTEIN OmpA OF KLEBSIELLA PNEUMONIAE ASSOCIATED WITH THE HCG HORMONE OR A COMPOUND INVOLVED IN CELL PROLIFERATION OR FERTILITY
08/31/2000WO2000050067A1 Method and composition for the regulation of hepatic and extrahepatic production of insulin-like growth factor-1
08/31/2000WO2000050051A2 Reovirus for the treatment of cellular proliferative disorders
08/31/2000WO2000050046A1 Stabilized oral pharmaceutical composition containing iodide and iodate and method
08/31/2000WO2000050033A2 Anti-tumor synergetic composition
08/31/2000WO2000050032A1 Antitumour synergistic composition
08/31/2000WO2000050022A2 Treatment regimen for hormone-sensitive cancers
08/31/2000WO2000049937A2 Trpm-2 antisense therapy
08/31/2000WO2000028029A3 Cell surface glycoproteins
08/31/2000WO2000026236A3 Method of modulating cell differentiation or neoplastic transformation by altering cadherin-11 expression or function
08/31/2000WO2000023112A9 Modulation of gene expression by combination therapy
08/31/2000WO2000018932A9 Receptor based antagonists and methods of making and using
08/31/2000WO2000018914A3 Novel dkr polypeptides
08/31/2000WO2000018803A3 Antibodies to mammalian langerhans cell antigen and their uses
08/31/2000WO2000018795A9 Compositions and methods for wt1 specific immunotherapy
08/31/2000WO2000012507A3 Pyrrolobenzodiazepines
08/31/2000WO2000007996A3 Pyrazoles as estrogen receptor modulators
08/31/2000DE19908762A1 Verwendung von Dienogest in hoher Dosierung Use of dienogest in high doses
08/31/2000CA2850318A1 Trpm-2 antisense therapy
08/31/2000CA2615684A1 Reovirus for the treatment of cellular proliferative disorders
08/31/2000CA2371814A1 Trpm-2 antisense therapy
08/31/2000CA2366697A1 Treatment regimen for hormone-sensitive cancers
08/31/2000CA2365026A1 Virus vector
08/31/2000CA2364712A1 Platinum (ii) compounds
08/31/2000CA2364708A1 Anti-cancer dihydroquinazoline derivatives
08/31/2000CA2363621A1 A novel inhibitor of programmed cell death
08/31/2000CA2363605A1 Androgen-induced suppressor of cell proliferation and uses thereof
08/31/2000CA2363112A1 Neutrokine-alpha and neutrokine-alpha splice variant
08/31/2000CA2363106A1 Mdm interacting protein and methods of use thereof
08/31/2000CA2362906A1 Dna encoding snorf25 receptor
08/31/2000CA2362533A1 Gene sequence variations with utility in determining the treatment of disease
08/31/2000CA2362520A1 Novel component of von hippel-lindau tumor suppressor complex and scf ubiquitin ligase
08/31/2000CA2361828A1 Anti-tumor synergetic composition
08/31/2000CA2361826A1 Antitumour synergistic composition
08/31/2000CA2361396A1 Compositions, kits, and methods relating to the human fez1 gene, a novel tumor suppressor gene
08/30/2000EP1031835A1 Diagnostic, prognostic, and therapeutic methods for solid non-lymphoid tumors and their metastases.
08/30/2000EP1031352A2 Use of desmopressin in the preparation of a metastatic dissemination inhibitor medicament during cancer surgery
08/30/2000EP1031347A1 Transnasal transport/immunisation with highly adaptable carriers
08/30/2000EP1030935A1 Antisense oligonucleotide modulation of human serine/threonine protein phosphatase gene expression
08/30/2000EP1030917A1 Transcriptionally regulated g protein-coupled receptor
08/30/2000EP1030911A1 Human aspartic proteases
08/30/2000EP1030859A1 Ras-binding protein (pre1)
08/30/2000EP1030845A1 Heterocyclic compounds having mmp and tnf inhibitory activity
08/30/2000EP1030842A1 Metalloproteinase inhibitors
08/30/2000EP1030839A1 Use of alkylated iminosugars to treat multidrug resistance
08/30/2000EP1030836A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
08/30/2000EP1030686A2 Lyophilizate of lipid complex of water insoluble porphyrins
08/30/2000EP1030684A1 Modified antibodies with enhanced ability to elicit an anti-idiotype response
08/30/2000EP1030681A1 Method and compositions for inhibiting angiogenesis and treating cancer
08/30/2000EP1030680A1 Treatment of kaposi's sarcoma with il-12
08/30/2000EP1030679A1 Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
08/30/2000EP1030675A2 Treatment of hematologic disorders
08/30/2000EP1030674A1 METHODS FOR TREATMENT OF TUMORS AND TUMOR CELLS USING $i(EX VIVO) ACTIVATED T CELLS
08/30/2000EP1030670A1 Use of vitamin d derivatives to enhance efficacy of cytotoxic agents
08/30/2000EP0821680B1 Novel taxoids, preparation thereof, and pharmaceutical compositions containing same
08/30/2000EP0799198B1 Anti-inflammatory compounds
08/30/2000EP0742789B1 Pharmaceutically active compounds and liposomes, and methods of use therof
08/30/2000EP0642343B1 Acridine carboxamides for the treatment of cancer
1 ... 1886 1887 1888 1889 1890 1891 1892 1893 1894 1895 1896 1897 1898 1899 1900 1901 1902 1903 1904 1905 1906 ... 2211